Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Profusa, Inc.

  • NEW YORK, New York
  • Public · NASDAQ: PFSA
$1.3MMarket cap
$100.0KRevenue · FY2024
-$35.8MNet income
PFSANASDAQ
2025IPO

About Profusa, Inc.

Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2024
$100.0K
Net income
-$35.8M
Total assets
$3.8M
Market cap
$1.3M

Source: SEC EDGAR · updated Jun 8, 2026

NASDAQ: PFSA

15-minute delayed · data by Polygon.io

Market cap
$1.3M
Open
Day range
Prev close
Volume
IPO date
Jul 14, 2025

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review Profusa, Inc..

Write a review
Explore

Similar companies

Browse all →